VXRT Vaxart Inc
Price (delayed)
$0.35
Market cap
$79.78M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.33
Enterprise value
$72.08M
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can
Highlights
VXRT's revenue has surged by 71% since the previous quarter
VXRT's gross profit has surged by 71% since the previous quarter
VXRT's quick ratio has dropped by 77% year-on-year and by 10% since the previous quarter
The equity has contracted by 14% from the previous quarter
Key stats
What are the main financial stats of VXRT
Market
Valuations
Earnings
Shares outstanding
227.95M
Market cap
$79.78M
Enterprise value
$72.08M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.35
Price to sales (P/S)
2.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.51
Revenue
$28.7M
Gross profit
$28.7M
Operating income
-$66.29M
Net income
-$66.95M
EBIT
-$66.69M
EBITDA
-$57.84M
Free cash flow
-$45.32M
Per share
Balance sheet
Liquidity
EPS
-$0.33
EPS diluted
-$0.33
Free cash flow per share
-$0.22
Book value per share
$0.26
Revenue per share
$0.14
TBVPS
$0.78
Total assets
$166.39M
Total liabilities
$107.46M
Debt
$17.53M
Equity
$58.93M
Working capital
-$22.62M
Debt to equity
0.3
Current ratio
0.75
Quick ratio
0.7
Net debt/EBITDA
0.13
Margins
Efficiency
Dividend
EBITDA margin
-201.5%
Gross margin
100%
Net margin
-233.3%
Operating margin
-231%
Return on assets
-50%
Return on equity
-101.8%
Return on invested capital
-103.5%
Return on capital employed
-88.3%
Return on sales
-232.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VXRT stock price
How has the Vaxart stock price performed over time
Intraday
-6.04%
1 week
-24.65%
1 month
-31.28%
1 year
-71.77%
YTD
-47.14%
QTD
-14%
Financial performance
How have Vaxart's revenue and profit performed over time
Revenue
$28.7M
Gross profit
$28.7M
Operating income
-$66.29M
Net income
-$66.95M
Gross margin
100%
Net margin
-233.3%
The operating margin has surged by 80% year-on-year and by 46% since the previous quarter
VXRT's net margin has soared by 79% YoY and by 46% QoQ
VXRT's revenue has surged by 71% since the previous quarter
VXRT's gross profit has surged by 71% since the previous quarter
Growth
What is Vaxart's growth rate over time
Valuation
What is Vaxart stock price valuation
P/E
N/A
P/B
1.35
P/S
2.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.51
The EPS has increased by 42% year-on-year and by 20% since the previous quarter
The P/B is 61% below the 5-year quarterly average of 3.7 and 47% below the last 4 quarters average of 2.7
The equity has contracted by 14% from the previous quarter
VXRT's P/S is 99% below its 5-year quarterly average of 468.5 and 79% below its last 4 quarters average of 12.4
VXRT's revenue has surged by 71% since the previous quarter
Efficiency
How efficient is Vaxart business performance
The return on sales has surged by 79% year-on-year and by 46% since the previous quarter
The ROA has grown by 32% YoY and by 20% from the previous quarter
The company's return on invested capital rose by 12% YoY and by 9% QoQ
Vaxart's ROE has increased by 8% from the previous quarter and by 6% YoY
Dividends
What is VXRT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VXRT.
Financial health
How did Vaxart financials performed over time
The company's total assets is 55% higher than its total liabilities
The company's total assets has surged by 81% YoY
Vaxart's current ratio has shrunk by 77% YoY and by 10% QoQ
VXRT's debt is 70% lower than its equity
Vaxart's debt to equity has decreased by 14% YoY but it has increased by 11% QoQ
The equity has contracted by 14% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.